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Abstract
Background Body fluid and structural imaging biomarkers give information on
neurodegeneration.The relationship over time is not known in multiple sclerosis.
Objective To investigate the temporal relationship of elevated cerebrospinal fluid
(CSF) neurofilament protein (Nf) levels, a biomarker for axonal loss, with magnetic
resonance imaging (MRI) atrophy measures.
Methods In patients with multiple sclerosis CSF Nf heavy chain phosphoform levels
were quantified at baseline and dichotomised into ‘normal’ and ‘high’. Atrophy was
assessed by MRI at baseline and 15–year follow–up using SIENAX and FreeSurfer
software.
Results High baseline CSF NfH-SMI35 levels predicted pronounced atrophy at 15–
year follow up (OR 36, p<0.01), in absence of baseline brain atrophy (OR 28,
p<0.05), for the averaged MRI normalised brain volume (1.44 L vs 1.33 L, p<0.05),
normalised grey matter volume (0.77 L vs 0.69 L, p<0.01) and putamen (12.7 mL vs
10.7 mL, p<0.05). Region specific calculations including the spinal cord showed that
a power of >80% is reached with 14–50 patients.
Conclusion These data suggest that high CSF NfH levels are an early predictor of
later brain and spinal cord atrophy using structural imaging biomarkers and can be
investigated in reasonably sized patient cohorts.
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Introduction
The assessment of clinical function in patients suffering from multiple sclerosis (MS)
relies on validated clinical scales1. The major pathological process driving irreversible
loss of function is progression of neurodegeneration2. The in vivo quantification of
mechanisms of neurodegeneration relies on indirect data from biomarkers3. A strong
study design in demyelination combines the well timed use of body fluid biomarkers
and structural imaging biomarkers4. Neurofilament (Nf) proteins have been validated
as a body fluid biomarker for neurodegeneration in multiple sclerosis3;5. Disintegration
of neurons and axons causes proteolysis and release of neurofilament proteins into the
adjacent body fluid compartment6. In the acute phase inflammation related oedema
and glial activation can mask imaging biomarker quantification of atrophy7. With time
and resolution of inflammation atrophy becomes more visible and quantification more
reliable8–10. Therefore a logical sequence of events is that neurodegeneration in MS
causes a rise of Nf and irreversible disability which is followed over time by central
nervous system (CNS) atrophy4.
Consistent with this line of argumentation cross–sectional data from patients with MS
did show elevated Nf levels11. The baseline data did however fail to show a relationship
between CSF NfH protein concentration and brain atrophy. Subsequent 3–year follow–up
data demonstrated that elevated CSF Nf heavy chain (NfH) protein concentrations were
significantly related to irreversible disease progression12. This relationship between CSF
NfH and disability has since been confirmed by other groups3;5. Long–term clinical data
of our original cohort confirmed the prognostic value of CSF NfH levels13. Importantly,
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the 15 year follow–up data revealed that the strongest relationship of phosphorylated
CSF NfH levels was with the visual, pyramidal, cerebellar and sensory systems13. It
was discussed that degeneration of the very long axons of the posterior columns and
spinothalamic tracts may be a relevant source for releasing CSF NfH.
The pathological process responsible for brain atrophy following axonotmesis is bi–
directional trans–synaptic axonal degeneration14. Therefore, extending on our 3–year
follow–up data, the aim of the present study was to test if high CSF NfH levels at baseline
would predict more severe CNS atrophy after 15–years.
Material and Methods
This study was approved by the Institutional Review Board and written informed consent
was obtained from all patients.
Patients Fifteen patients from a previously reported cohort13 with clinically definite
MS15 agreed to participate in brain and spinal cord magnetic resonance imaging (MRI).
All patients have been started with disease modifying treatment (interferon beta). The
Expanded Disability Status Scale score (EDSS)16 was assessed at baseline and follow–
up. The disease course was classified as relapsing remmitting (RR), primary or secondary
progressive (PP/SP)11.
MRI At baseline a 1.5 T system (Siemens AG, Erlangen, Germany) and consisted
of an axial T1- and T2-weighted spin echo MRI with 3 mm slice thickness and 1x1
mm in-plane resolution. Brain atrophy and lesion load measurements were analysed as
described11. More severe atrophy was indicated by a smaller brain parenchymal fraction
(BPF = whole brain parenchymal volumeintracranial volume ).
At 15–years follow up MRI was performed on a 3 T whole body system (GE Signa
HDxt, Milwaukee, WI, USA). The detailed acquisition parameters have been described
previously17. Lesion volumes were automatically quantified using ’k nearest neighbour
classification with tissue type priors’ (kNN-TTP)18. Normalized brain volumes (NBV),
grey matter volumes (NGMV) and white matter volumes (NWMV) were determined with
SIENAX (part of FSL 5.04, fsl.fmrib.ox.ac.uk) after lesion filling19. We did use FIRST to
determine the normalised deep grey matter volumes (NDGMV). In addition, mean upper
cervical cord area (MUCCA) was measured as a measure of spinal cord atrophy20;21.
CSF Samples of CSF were obtained by routine lumbar puncture. Aliquots of CSF
were stored at -80◦C until assayed. Levels of NfH phosphoforms were quantified by
ELISA22. Phosphoforms were indicated with the capturing antibody in the superscript,
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with SMI34 for hyperphosphorylated NfH (NfHSMI34 ) and SMI35 for phosphorylated
NfH (NfHSMI35 ) adhering to a published nomenclature22. Consensus guidelines were
followed for analysis and classification of CSF oligoclonal bands (OCB)23. General CSF
findings were summarised as recommended24.
Data analysis SAS software (v9.4) was used for Statistical analyses and preparation
of figures. Non–Gaussian data were reported as median and 25–75 % interquartile range
(IQR), normally distributed data as mean ± standard deviation (SD). Two tailed tests
were used and a p–value of <0.05 accepted as statistically significant.
Our previously published hypothesis on the prognostic value of CSF NfH levels
was tested. Consistent with our previous publications high CSF NfHSMI35 levels were
defined as ≥ 20 pg/mL and high CSF NfHSMI34 levels as ≥ 11 pg/mL12;13. Group
comparisons were made according to distribution either using the exact non–parametric
Wilcoxon Two–Sample Test or the t–test. In addition, general linear models (GLM) were
applied to the segmented FreeSurfer data to detect possible localised atrophy. Power
calculations were performed using proc power in SAS with alpha set to 0.05 to calculate
the total sample size required to reach a power of 80%.
Results
The baseline characteristics of the entire patient cohort are summarised in Table
1. Patients were dichotomised at baseline according to pre–defined CSF NfH cut-
off values12;13. Patient characteristics for this biomarker driven dichotomisation are
presented for baseline and 15–year follow up.
Patient characteristics at baseline
Five patients had normal and ten had elevated CSF NfHSMI35 levels at baseline. For CSF
NfHSMI34 elevated levels were present in eight and normal in seven patients (Table 2).
The disease course was RR in seven, SP in six and PP in two of the patients. The time
delay from the last relapse to CSF sampling was long (median 18 months) and not related
to CSF NfHSMI35 or CSF NfHSMI34 levels. Age did not differ significantly between the
CSF neurofilament subgroups p=0.84. Patients with high CSF NfHSMI35 levels had a
smaller BPF (more atrophy) compared to those with normal CSF NfHSMI35 levels but
this narrowly failed to reach statistical significance (p=0.052, Table 2).
Patients with high CSF NfHSMI35 levels had a worse EDSS compared to those with
normal CSF NfHSMI35 levels (p=0.043).
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Table 1. Characteristics of the patients with MS. The median (IQR) or n (%) are shown. Red
cell count = RCC, white cell count = WCC, oligoclonal bands = OCB. Type 2 OCB =
intrathecal IgG synthesis only, type 4 OCB = more IgG in CSF compared to serum, type 5
OCB = monoclonal band in CSF, MRI = magnetic resonance imaging, BPF = brain
parenchymal fraction, CSF = cerebrospinal fluid, NfH = neurofilament heavy chain, EDSS =
Expanded Disability Status Scale score. In addition the time interval between the last clinical
relapse and sampling of CSF is given in months.
Baseline characteristics
Female:Male 10:5
Age (years) 45 (35–49)
Age at onset (years) 28.7 (25.4–37.6)
Disease duration (years) 10 (7–20)
Medication Corticosteroids during relapse n=13 (77%)
Interferon beta n=5 (33%)
Endoxan n=1 (6%)
EDSS 4.5 (1.5-6.5)
Last relapse (months) 41 (18–144)
CSF total protein 0.088 (0.075–0.093)
CSF RCC 4 (0–219)
CSF WCC 5 (3–15)
CSF OCB type 2 n=9 (60%)
type 4 n=5 (33%)
type 5 n=1 (7%)
CSF NfHSMI35 (pg/ml) 31.0 (147)
CSF NfHSMI34 (pg/ml) 11.0 (5–19)
MRI BPF 0.81 (0.79–0.86)
Table 2. High baseline CSF NfHSMI35 levels are related to clinical but not MRI parameters.
The mean ± standard deviation and median (range) are shown. * = p<0.05, ** = p<0.01.
CSF NfHSMI35 CSF NfHSMI34
Normal High Normal High
N 5 10 8 7
Age 42±8 43±7 42±8 44±7
EDSS 2.0 (1.5–3.0) 6.0 (4.5–6.5)* 4.1 (2.3–5.3) 6.0 (1.0–7.0)
MRI BPF, L 0.84±0.03 0.79±0.04 0.81±0.04 0.81±0.04
There was no correlation between age and the CSF concentration of either
NfHSMI35 (R=0.17, p=0.55) or NfHSMI34 (R=0.09, p=0.74). There was no correlation
of the baseline CSF NfHSMI35 or CSF NfHSMI34 levels with either the EDSS and the
BPF.
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Table 3. High baseline CSF NfHSMI35 levels predict accelerated CNS atrophy at 15–years
follow–up. * = p<0.05, ** = p<0.01. NBV = normalised brain volumes, NGMV = normalised
grey matter volumes, NWMV = normalised white matter volumes, MUCCA = mean upper
cervical cord area, NDGMV = normalised deep grey matter volumes.
CSF NfHSMI35 CSF NfHSMI34
Normal High Normal High
N 5 10 8 7
Age 56±8 57±7 56±7 58±7
EDSS 3 (2.5–4.3) 6.3 (5.6–7.5)** 4.5 (2.9–6.0) 7.5 (3 – 7.5)
∆ EDSS 1.0 (1.0–1.0) 0.25 (0–1.5) 0.75 (0-1.75) 1.0 (0–2.5)
MRI NBV, L 1.44±0.08 1.33±0.07* 1.37±0.10 1.37±0.08
MRI NGMV, L 0.77±0.04 0.69±0.05** 0.72±0.06 0.71±0.05
MRI NWMV, L 0.68±0.05 0.64±0.04 0.65±0.04 0.65±0.44
MRI MUCCA, mm2 70.34±7.96 62.82±8.03 65.88±7.83 65.02±10.19
NDGMV, mL 59.02±8.70 52.77±3.85 54.89±5.62 54.81±7.58
Accumbens, mL 1.13±0.38 0.85±0.29 0.91±0.27 0.98±0.42
Amygdala, mL 3.71±0.58 3.46±3.71 3.52±0.35 3.58±0.57
Caudate, mL 8.56±1.43 7.49±1.13 7.78±1.34 7.93±1.35
Hippocampus, mL 9.79±1.45 8.40±1.25 8.84±1.48 8.89±1.49
Pallidum, mL 4.70±0.91 3.84±0.44 4.17±0.80 4.08±0.70
Putamen, mL 12.68±2.22 10.69±1.37* 11.32±1.63 11.39±2.28
Thalamus, mL 18.44±2.61 18.03±2.12 18.35±1.98 17.95±2.59
Cortical thickness, mm 2.43±0.05 2.39±0.11 2.38±0.08 2.43±0.11
Frontal, mm 2.51±0.03 2.41±0.09 2.42±0.10 2.46±0.09
Precentral, mm 2.49±0.14 2.36±0.13 2.37±0.16 2.40±0.12
Postcentral, mm 2.01±0.10 2.00±0.11 1.97±0.07 2.03±0.14
Parietal, mm 2.31±0.05 2.31±0.13 2.28±0.07 2.35±0.15
Temporal, mm 2.73±0.15 2.70±0.14 2.68±0.10 2.75±0.17
Occipital, mm 2.00±0.15 2.06±0.12 1.98±0.10 2.11±0.12
Cingulate, mm 2.66±0.04 2.55±0.14 2.59±0.17 2.56±0.10
Insula, mm 3.05±0.05 2.95±0.10 2.98±0.09 2.98±0.11
Patient characteristics at 15 year follow–up
Patients with high CSF NfHSMI35 levels at baseline were significantly more disabled at
15 year follow–up compared to those with normal CSF NfHSMI35 levels (p=0.01, Table
3). Progression on the EDSS was, however minimal and changes did not reach statistical
significance (Table 3). The disease course changed from RR to SP in two of the patients.
One patient thought to have a PP disease course at baseline developed clinical and MRI
documented relapses and was reclassified as having a SP disease course. This patient was
also treated with corticosteroids during relapses.
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Brain atrophy was significantly more pronounced in the patients with high CSF
NfHSMI35 levels compared to those with normal CSF NfHSMI35 levels for the NGMV
(p=0.007) and the NBV (p=0.014). Significance was not reached when comparing the
NWMV (p=0.11) and MUCCA (p=0.12) between patients with high or normal CSF
NfHSMI35 levels.
No statistical significant relationships were found for any of the demographic,
clinical or MRI parameter for the comparison of patients with high or normal CSF
NfHSMI34 levels (Table 3). Likewise, a subgroup analysis considering the clinical disease
course did not reveal any differences, but statistical power was poor for this subgroup
analysis (RR n=5, SP n=9). A subgroup analysis was not possible for PP (n=1).
There was an inverse correlation of the absolute concentration of baseline CSF
NfHSMI35 levels with the follow–up NGMV (Figure 1, Spearman R=-0.62, p=0.014).
No significant correlation was found for absolute concentration of CSF NfHSMI34 . There
were no significant correlations of either neurofilament phosphoform with age or EDSS
at follow–up.
The relationship between dichotomised CSF NfHSMI35 levels and progression of brain
atrophy on MRI is summarised in Figure 2. At baseline 12/15 (80%) of MS patients had
a normal BPF. There were signs of atrophy only in 3/15 (20%) all of whom had high
CSF NfHSMI35 levels (Figure 2, red dots in yellow shaded area). At 15–year follow–
up six patients with high CSF NfHSMI35 levels developed more pronounced atrophy of
the NGMV (Figure 2, red dots in blue shaded area). Four patients with normal CSF
NfHSMI35 levels remained within the normal range for age (Figure 2, green triangles in
white area). Taken together high baseline CSF NfHSMI35 levels have an odds-ratio of 36
(95%CI 1.8-731.6, p=0.0067) for more pronounced NGMV atrophy after 15–years. If
the three cases with manifest brain atrophy at baseline are excluded the odds ratio is 28
(95%CI 1.4-580.6, p=0.0149).
There was significant more atrophy of the putamen in patients with high baseline
CSF NfHSMI35 levels compared to those with normal CSF NfHSMI35 levels (p<0.05,
supplementary Table 1). For all other regions of interest statistical significance was
not reached probably due to small group size. Consistently, however smaller average
thickness data, suggestive of localised atrophy were observed in patients with high
CSF NfHSMI35 levels for the accumbens, amygdala, caudate, hippocampus, pallidum
and thalamus (supplementary Table 1). Likewise absolute cortical thickness values were
smaller, suggesting localised atrophy, in patients with high CSF NfHSMI35 levels for the
frontal, precentral, postcentral, temporal areas, the cingulate and insula.
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Figure 1. Brain atrophy and CSF NfHSMI35 levels. (A) Higher CSF NfHSMI35 levels were
seen in those patients with a higher BPF indicating absence of significant brain atrophy at
baseline (Table 2). (B) 15 years later those patients with high CSF NfHSMI35 levels developed
more pronounced atrophy of the NGMV (p<0.01, Table 3) which also correlated inversely
with the absolute CSF NfHSMI35 levels (R=-0.62, p=0.014). The dashed horizontal reference
line indicates the predefined CSF NfHSMI35 cut–off value of 20 pg/mL 12.
Power calculations for detecting localised atrophy
Power calculations were performed to estimate how many patients were needed to test
whether or not there is a statistical relationship between dichotomised baseline CSF NfH
levels and localised atrophy on MRI. Table 4 summarises the actual power of the present
study and numbers needed to reach a desired power of 80%.
The power calculations are grouped into those areas which will be potentially be
possible testing given a original cohort size of n=51 and those were testing will likely
be futile.
A sample size of n < 51 is sufficient to test the predictive value of dichotomised
baseline CSF NfHSMI35 levels for atrophy of the MRI NMV, NGMV, MUCCA,
hippocampus, pallidum, putamen, frontal lobe, precentral cortical thickness, cingulate
and insula.
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Figure 2. Progression of atrophy between baseline (yellow shaded area) and 15–year
follow–up (blue shaded area) in relation to dichotomised CSF NfHSMI35 levels (high = red
dots, normal = green triangles).
Discussion
The long–term follow–up data of this cohort are unique because they provide evidence
that development of brain atrophy is preceded by rise of a clinically relevant biomarker
for axonal damage. To better develop the argument one has to recall the principal
hypothesis underlying this research. An increase of CSF neurofilament levels was thought
to reflect on axonal disintegration3;5;25. Logically, therefore one would expect that those
patients who suffer axonal degeneration at baseline also suffer from disability as axonal
loss is hold responsible26. The inflammatory plaques found in MS can however not only
cause axonal degeneration, but also demyelination and conduction block from which
patients may recover. To be attributable to axonal degeneration disability will therefore
need to be sustained, which it was in this study. To close the argument one needs to
demonstrate that elevated CSF neurofilament levels also relate over time to development
of more severe brain and or spinal cord atrophy. This relationship we were unable to
demonstrate at baseline and three year follow–up11;12. Only 15–years later the association
between rise of CSF neurofilament levels and subsequent brain atrophy emerged.
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Table 4. Sample sizes required to test the predictive value on dichotomised CSF
NfHSMI35 levels on subsequent localised CNS atrophy. The original size of this cohort was
n=51. Power calculations were based on alpha=0.05 for a two–sample t Test.
MRI Actual Desired Numbers
Readout power power required
MRI NBV, L 61% 80 % 21
MRI NGMV, L 84% 80 % 14
MRI NWMV, L 27% 80 % 52
MRI MUCCA, mm2 33% 80 % 43
NDGMV , mm 24% 80 % 55
Accubens , mm 24% 80 % 59
Amygdala , mm 5% 80 % > 100
Caudate , mm 24% 80 % 59
Hippocampus , mm 36% 80 % 39
Pallidum, mm 37% 80 % 35
Putamen, mm 34% 80 % 39
Thalamus, mm 6% 80 % > 100
Cortical thickness, mm 14% 80 % > 100
Frontal, mm 82% 80 % 14
Precentral, mm 33% 80 % 41
Postcentral, mm 5% 80 % > 100
Temporal, mm 6% 80 % > 100
Cingulate, mm 56% 80 % 25
Insula, mm 65% 80 % 20
There is a debate on the time course of axonal degeneration in the central nervous
system (CNS). The relative timing of these cellular events differs considerably between
the CNS and peripheral nervous system27;28. In general terms the CNS response is much
slower29–31. In MS there is emerging evidence that this is related to presence of trans–
synaptic axonal degeneration14;32. The association of development of disability related to
long tract spinal cord axons13 suggests that the dominant source of CSF NfHSMI35 levels
at baseline is likely to be of spinal cord origin. Therefore axonal damage far remote from
the brain grey matter would be a convenient explanation for high CSF NfHSMI35 levels
at baseline, association with functional system disability on the EDSS and a long time
lag through trans–synaptic axonal degeneration until brain grey matter atrophy becomes
manifest on MRI.
Conceptionally comparable, but and on a much shorter time scale, this association
was already shown for the visual system. An elevation of plasma NfHSMI35 had been
associated with poor visual acuity following optic neuritis and preceded optic disc
pallor on funduscopy33. This clinical observation has since been confirmed quantitatively
using optical coherence tomography34. But then distance from the optic nerve to the
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brain is much closer compared to the distal spinal cord, substantially shortening time
requirements for trans–synaptic axonal degeneration.
Importantly, the power calculations preformed suggest that it will be possible testing
the hypothesis that dichotomised baseline CSF NfHSMI35 levels may be predictive of
more localised CNS atrophy (Table 4). The association with the putamen, where motor
fibres interconnect has been shown in this study. Extending on present finding, it would be
particularly interesting testing a likely association of high baseline CSF NfHSMI35 levels
with atrophy of the precentral gyrus (Brodman area 4) as the pathway of trans–synaptic
axonal degeneration would predict. Another interesting new finding was the unexpected
strong association of CSF NfHSMI35 levels with frontal lobe atrophy. This has not
previously been reported in MS, but was earlier brought out be a systematic review on the
CSF neurofilament data in dementia35. Impairment of frontal lobe function and cognition
is also an important feature of MS pathology.
This study did not find CSF Nf levels to be influenced by factors previously reported
in the literature, such as time from last relapse or disease course. This former was most
likely due to the long delay between relapse on CSF sampling, far exceeding the reported
crucial three months. The latter might be a negative finding due to the low statistical
power for subgroup analyses of clinical groups. Of note those patients with high CSF
NfHSMI35 levels had a, non-significant, lower MRI BPF at baseline compared to those
with normal CSF NfHSMI35 levels. Also significance was missed in this study, this is
likely related to power.
In the present study findings were only significant for CSF NfHSMI35 but not for
CSF NfHSMI34 . The argument might be valid that this could only be a statistical
phenomenon. A known autoimmune phenomenon might also be considered25. Presence
of auto-antibodies against NfH can cover epitopes relevant to detection by immunological
techniques. Because hyperphosphorylation of tissue NfH has been related to pathology
in many neurodegenerative diseases (reviewed in25) further research in this field is
warranted.
There are however important limitations to the present study. First there might be a
potential bias towards more severely disabled patients. At both time points those patients
with high CSF NfHSMI35 levels also were those which had a poorer EDSS. From a
biomarker point of view this bias might be expected because of the association between
high CSF neurofilament levels and disability3;5;25. From a clinical point of view one
would like to see these results confirmed in a cohort of less severe disabled patients and
also more rapidly progressing patients prior to extrapolating from present data to patients
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with MS in general. Likewise, the development of MRI techniques from 1.5 T to 3 T in
this study did not permit to calculate progression on the same variable. This will remain
a problem as the average life time of a magnet is about 10 years and therefore short of
the long–term clinical follow–up time. Another potential bias is the drop out of patients
from the original cohort. This drop out was at least in part related to the request for a
second lumbar puncture at three years follow–up12. This bias might also be related to
the trend of current diagnostic criteria relying on non invasive examinations, with MRI
representing the current consensus cornerstone of MS diagnostics. We would be hesitant
to draw any conclusion from potential effect of treatment on brain atrophy from this
small cohort with heterogenous treatments streched over a long time. The drop-out also
reduced the power of the study such that our attempts to investigate for more localised
atrophy, for example in the primary motor cortex failed to reach statistical significance.
This important limitation is further highlighted by the power calculations. The larger
standard deviation for the MUCCA already exemplifies to what extend the accuracy of a
method impacts on the required sample size. Compared to the tighter, smaller standard
deviation, data for brain volumes requiring only about 21 patients, 43 are needed to be
in a powerful enough situation to test for the hypothesised association between high
baseline CSF NfHSMI35 levels and subsequent spinal cord atrophy. These limitations
discussed, the present study was sufficiently powered (power 84%, alpha 0.05) to test for
a relationship between dichotomised baseline CSF NfHSMI35 levels and NGMV atrophy.
Taken together the 15 year follow up data strengthen the argument that elevation of
CSF neurofilament protein levels in patients with multiple sclerosis are related to axonal
loss responsible for sustained disability and precede CNS atrophy by abuot 3 to 15 years
(Figure 3).
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Figure 3. Model suggesting that development of disability related to axonal degeneration
directly causes an increase of CSF neurofilament levels. Elevated neurofilament levels
precede global brain atrophy on MRI.
Supplemental material
Supplementary data available from the Journal’s website.
Table S1 Localised brain atrophy of FreeSurfer data at 15-years follow up for dichotomised
CSF NfH phosphoform data at baseline The median (IQR) are shown, *= p<0.05.
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